Symbol
| KDR
| contributors: mct - updated : 19-05-2017
|
HGNC name
| kinase insert domain receptor (a type III receptor tyrosine kinase)
|
HGNC id
| 6307
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
constitutional
| somatic mutation
|  
|  
|  
|
in juvenile hemangioma | tumoral
|  
|  
| --over
|  
|
in invasive ovarian cancer | tumoral
|  
| amplification
|  
|  
|
coamplification of PDGFRA or KDR with KIT may be clinically useful novel molecular markers in medulloblastomas and primitive neuroectodermal tumors | constitutional
|  
|  
| --low
|  
|
in coronary artery disease where cardiac tissue has been subjected to prolonged or chronic hypoxia | constitutional
|  
|  
| --low
|  
|
loss of expression of FLT1, moderate expression of KDR and high concentration of nitrate associated with aneurysm formation | constitutional
|  
|  
| --low
|  
|
decreased expression of FLT1 in decidua and weaker VEGFA and KDR expression in placental villi and decidua may be associated with early pregnancy loss | |
Susceptibility
|
to coronary heart disease |
Variant & Polymorphism
SNP
| SNP1192 and SNP1719 associated with risk of coronary heart disease |
|
|
Candidate gene
| early marker for endothelial cell progenitors |
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
tumor | | | |
blocking EFNB2 signaling in tumors might represent an intriguing strategy to interfere simultaneously with both KDR and FLT4 function that could be used as an alternative or combinatorial anti-angiogenic treatment for tumor therapy | tumor | | | |
blocking ephrin-B2 reverse signaling may be an attractive alternative or combinatorial anti-angiogenic therapy strategy to disrupt KDR function in tumour angiogenesis | tumor | | | |
inhibition of tyrosine phosphorylation of KDR by wogonin, correlated with a significant decrease in VEGF-triggered phosphorylated forms of ERK, AKT1 and MAPK14, associated with suppression of tumor growth |
| | |